Catalyst
Slingshot members are tracking this event:
Mallinckrodt (MNK) to Initiate Phase 2 Study of Acthar Gel in Amyotrophic Lateral Sclerosis (ALS) in H1 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| MNK |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 03, 2017
Occurred Source:
https://clinicaltrials.gov/ct2/show/NCT03068754
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 2, Initiation, Acthar Gel, Amyotrophic Lateral Sclerosis, Als
